The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients
Open accessAbstract
In the era of immunotherapies there is an urgent need to implement the use of circulating biomarkers in clinical practice to facilitate personalized therapy and to predict treatment response. We conducted a prospective study to evaluate the usefulness of circulating exosomal‐PD‐L1 in melanoma patients’ follow‐up. We studied the dynamics of exosomal‐PD‐L1 from 100 melanoma patients by using an enzyme‐linked immunosorbent assay. We found that PD‐L1 was secreted through exosomes by melanoma cells. Exosomes carrying PD‐L1 had immunosuppressive properties since they were as efficient as the cancer cell from which they derive at inhibiting T‐cell activation. In plasma from melanoma patients, the level of PD‐L1 (n= 30, median 64.26 pg/mL) was significantly higher in exosomes compared to soluble PD‐L1 (n= 30, 0.1 pg/mL). Furthermore, exosomal‐PD‐L1 was detected in all patients whereas only 67% of tumour biopsies were PD‐L1 positive. Although baseline exosomal‐PD‐L1 levels were not associated with clinic‐pathologic characteristics, their variations after the cures (ΔExoPD‐L1) correlated with the tumour response to treatment. A ΔExoPD‐L1 cut‐off of> 100 was defined, yielding an 83% sensitivity, a 70% specificity, a 91% positive predictive value and 54% negative predictive values for disease progression. The use of the cut‐off allowed stratification in two groups of patients statistically different concerning overall survival and progression‐free survival. PD‐L1 levels in circulating exosomes seem to be a more reliable marker than PD‐L1 expression in tumour biopsies. Monitoring of circulating exosomal‐PD‐L1 may be useful to predict the tumour response to treatment and clinical outcome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles
Colombo, M., Raposo, G., & Théry, C. (2014) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-101512-122326 · Cited by 6,186
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Exosomes: composition, biogenesis and function
Théry, C., Zitvogel, L., & Amigorena, S. (2002) · Nature Reviews Immunology · doi:10.1038/nri855 · Cited by 5,346
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, G., Huang, A. C., Zhang, W., Zhang, G., Wu, M., Xu, W., Yu, Z., Yang, J., Wang, B., Sun, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0392-8 · Cited by 2,813
Current knowledge on exosome biogenesis and release
Hessvik, N. P., & Llorente, A. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2595-9 · Cited by 2,362
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Cited by
The role of extracellular vesicles in cancer
Kalluri, R., & McAndrews, K. M. (2023) · Cell · doi:10.1016/j.cell.2023.03.010 · Cited by 664
Extracellular vesicles in immunomodulation and tumor progression
Marar, C., Starich, B., & Wirtz, D. (2021) · Nature Immunology · doi:10.1038/s41590-021-00899-0 · Cited by 584
The biology, function, and applications of exosomes in cancer
Liu, J., Ren, L., Li, S., Li, W., Zheng, X., Yang, Y., Fu, W., Yi, J., Wang, J., & Du, G. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.01.001 · Cited by 561
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75
Metadata
- Authors
- Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J.
- Venue
- Journal of Extracellular Vesicles
- Publisher
- Wiley
- Published
- 2020-01-07
- Volume
- 9
- Issue
- 1
- Pages
- 1710899-1710899
- ISSN
- 2001-3078 (ISSN-L)
- OpenAlex
- W2999741543
- Cited by
- 262
- References
- 30
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients. https://app.cochat.ai/papers/10.1080/20013078.2019.1710899
- The paper
- Cordonnier, M., Nardin, C., Chanteloup, G., Derangere, V., Algros, M., Arnould, L., Garrido, C., Aubin, F., & Gobbo, J. (2020). Tracking the evolution of circulating exosomal‐PD‐L1 to monitor melanoma patients. Journal of Extracellular Vesicles. https://doi.org/10.1080/20013078.2019.1710899
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.